ESPERITE (ESP) financial results for 2016 published

May 23, 2017 Financial Reports
annual_report_2016_banner

ESPERITE N.V. (Euronext: ESP, “Esperite” or “the Group”) has published today its Annual Report for the year ended 31 December 2016. The 2016 Annual Report is now available on the Company’s website www.esperite.com.

  • CryoSave’s EBITDA improved from € -2.5 million to € -0.7 million.
  • Genoma’s autonomous revenue increased by 80% up to a level of € 6.9 million.
  • Esperite’s consolidated revenue decreased by 4.5% to € 26.3 million.
  • Consolidated revenues were lower than expected but the gross margin is stable and gross profit increased by 2.3%.

Zutphen, the Netherlands – 23 May 2017

read more

Esperite secures external financing of up to EUR 9 million to support its commercial activity and development of innovative technologies

March 8, 2017 Financial Reports
_LA06534

Esperite secures external financing of up to EUR 9 million to support its commercial activity and development of innovative technologies

Total investment can reach EUR 13 million upon exercise of share subscription warrants

Zutphen, The Netherlands – 08 March 2017

read more

EN – ESPERITE financial results for 2014 published, metamorphosis completed, first positive forecast growth at €36mio Revenues (+30%) for 2015

March 17, 2015 Financial Reports , Group News
esperite_financial _summary_2014_teaser

ESPERITE (“Esperite N.V. (Euronext: ESP, “ESPERITE” or “the Company”) strengthens market position of Genoma with acquisitions of exclusive technologies for fully-certified groundbreaking genetic tests.

Stem cell historical CryoSave’s core business now profitable and improving.

Consolidated operations, headcount rationalization, integrated sales and marketing strategies, laboratories integration and processes automatization completed to yield enhanced performance and results.

Zutphen, The Netherlands – 17 March 2015

read more

Page 1 of 612345...Last »